CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference204 articles.
1. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature;van der Wekken;Crit. Rev. Oncol. Hematol.,2016
2. The impact of CRISPR-Cas9 on target identification and validation;Moore;Drug Discov. Today,2015
3. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery;Ahmad;Drug Discov. Today,2018
4. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression;Koo;Nucleic Acids Res.,2017
5. Antitumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR exon 20 insertions;Floc’h;Mol. Cancer Ther.,2018
Cited by 55 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles;Frontiers in Immunology;2024-08-30
2. Recent advances in CRISPR-Cas systems for colorectal cancer research and therapeutics;Expert Review of Molecular Diagnostics;2024-08-02
3. A review on molecular scissoring with CRISPR/Cas9 genome editing technology;Toxicology Research;2024-07-01
4. Developing a Novel Enzalutamide‐Resistant Prostate Cancer Model via AR F877L Mutation in LNCaP Cells;Current Protocols;2024-04
5. Insight into Iron, Oxidative Stress and Ferroptosis: Therapy Targets for Approaching Anticancer Strategies;Cancers;2024-03-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3